By Investigative Staff
The narrative surrounding the BRCA1 and BRCA2 genetic mutations has long been framed almost exclusively as a women’s health crisis. Historically synonymous with breast and ovarian cancer, the "pink ribbon" advocacy movement has successfully raised billions of dollars and saved countless lives. However, this gendered lens has inadvertently created a dangerous blind spot in clinical awareness and family health history.
Doug Bank, a veteran cancer advocate and survivor, is working to dismantle the myth that BRCA is a "women-only" issue. Through his personal journey—spanning from a testicular cancer diagnosis in his twenties to a BRCA2 discovery in his fifties—Bank highlights a critical medical reality: men are not just passive observers in the hereditary cancer narrative; they are vital links, carriers, and patients whose lives depend on early genetic literacy.
Main Facts: The Male Dimension of BRCA Mutations
The BRCA2 mutation, which Doug Bank carries, is a human gene that produces tumor suppressor proteins. When this gene is mutated, DNA damage may not be repaired properly, leaving cells more likely to develop additional genetic alterations that can lead to cancer. While the association with female breast and ovarian cancer is well-documented, the implications for men are often overlooked by both the public and the medical establishment.
Key facts regarding men and BRCA mutations include:
- Transmission: Men have a 50% chance of passing a BRCA mutation to each of their children, regardless of the child’s gender.
- Male Breast Cancer: Men with a BRCA2 mutation have a significantly higher risk of developing breast cancer than the general male population.
- Prostate Cancer: BRCA2 mutations are linked to more aggressive forms of prostate cancer, often occurring at an earlier age and with a higher likelihood of metastasis.
- Pancreatic Cancer: Both men and women with BRCA2 mutations face an elevated risk of pancreatic cancer, a disease that is notoriously difficult to detect in its early stages.
- The "Silent Link": In many families, the genetic pattern only becomes clear when the paternal history is scrutinized, as mutations can be "hidden" in male lineages where cancer may not manifest as visibly as in female relatives.
Chronology: A Life Defined by Advocacy and Discovery
Doug Bank’s intersection with the oncology world began in the late 1980s. At age 26, he was diagnosed with Stage I testicular cancer. While testicular cancer is generally not associated with BRCA mutations, the experience served as a baptism by fire into the complexities of the American healthcare system.
The Early Struggle (1990s): Following his surgery, Bank found himself navigating a medical landscape that pushed for aggressive, potentially unnecessary treatments. This lack of clear, patient-centered information led him to seek second opinions and eventually found a website and a non-profit organization dedicated to helping other men manage the fear and confusion of a cancer diagnosis.
The Advocacy Era (Early 2000s): Bank’s work expanded into the Adolescent and Young Adult (AYA) cancer space. It was during a meeting for the LIVESTRONG Young Adult Alliance—a national coalition of researchers and advocates—that he met Rochelle Shoretz, the founder of Sharsheret. Sharsheret was established to support Jewish women and families facing breast and ovarian cancer, a demographic at higher risk due to the prevalence of BRCA mutations in the Ashkenazi Jewish population (1 in 40, compared to 1 in 400 in the general population). At the time, Bank did not realize how central Sharsheret would become to his own family’s survival.
The Revelation (2009): The turning point occurred during a routine medical visit for Bank’s wife. When her physician inquired about Bank’s family history, a "pedigree" (a clinical family tree) was constructed. The data was staggering: his father had prostate cancer; his aunt had breast cancer; his grandmother had died young of cancer; and nearly every one of his father’s female cousins had faced breast or ovarian cancer. In 2009, testing confirmed that Bank carried the BRCA2 mutation.
The Family Impact (2010–2024): The knowledge proved bittersweet. Bank’s brother was diagnosed with pancreatic cancer; while the disease ultimately claimed his life, the knowledge of the BRCA2 mutation allowed for targeted treatments that extended his life by nearly five years. Furthermore, Bank and his wife made the controversial decision to test their children. Despite pushback from clinicians who feared inducing anxiety in young adults, the results showed two of his children were carriers. This knowledge allowed his daughter to undergo high-risk surveillance, leading to the early detection of a lump at age 24. Because of her known status, her concerns were taken seriously by specialists, leading to rapid, life-saving intervention.
The Final Diagnosis (2020s): At age 56, the genetic clock struck again. Bank was diagnosed with prostate cancer, a known risk of his BRCA2 status. His proactive monitoring, fueled by his genetic knowledge, allowed for early detection and management.
Supporting Data: The Science of Risk
Medical data reinforces Bank’s assertion that male genetic testing is a public health necessity. According to the National Cancer Institute and the Basser Center for BRCA, the lifetime risks for men with a BRCA2 mutation are significantly elevated:
- Prostate Cancer: Men with BRCA2 have a 20% to 25% lifetime risk of developing prostate cancer. More importantly, these cancers are often "high-grade," meaning they grow and spread more quickly than the standard "watchful waiting" varieties found in older men.
- Male Breast Cancer: While the general male risk is roughly 0.1%, the risk for BRCA2 carriers jumps to approximately 7% to 8%.
- Pancreatic Cancer: The risk increases to 2% to 7%, compared to 1.5% in the general population.
- The Ashkenazi Connection: Research shows that individuals of Ashkenazi Jewish descent have a 1 in 40 chance of carrying a BRCA1 or BRCA2 mutation. This makes the work of organizations like Sharsheret culturally vital, as they bridge the gap between religious community and clinical genetics.
Official Responses and Advocacy Perspectives
The medical community’s response to male BRCA testing has historically been tepid, often focusing on the "psychological burden" of testing. However, organizations like Sharsheret and the Men’s Leadership Council—of which Doug Bank is now a member—are pushing back against this paternalistic approach.
"Genetic information can create anxiety, but not knowing does not make the risk go away," Bank asserts. This sentiment is echoed by genetic counselors who argue that "knowledge is power." By identifying male carriers, clinicians can implement rigorous screening protocols, such as annual PSAs (Prostate-Specific Antigen tests) starting at age 40 and clinical breast exams.
Sharsheret has expanded its mission to include men, recognizing that a "family-centered" approach is the only way to effectively combat hereditary cancer. Their "Men’s Leadership Council" aims to educate men on how to be "proactive partners" in their family’s health, encouraging them to document family pedigrees and seek genetic counseling.
Implications: Changing the Conversation
The story of Doug Bank serves as a clarion call for a shift in how society views hereditary cancer. The implications of ignoring male BRCA carriers are profound:
1. The End of the "Gendered" Mutation:
Medical education must evolve to treat BRCA as a human mutation rather than a female one. When doctors only ask women about their family history, they miss 50% of the potential genetic data.
2. Early Intervention for the Next Generation:
As seen in the case of Bank’s daughter, male testing is often the "key" that unlocks early screening for daughters. If Bank had not been tested, his daughter’s lump at age 24 might have been dismissed as a benign cyst, a common mistake that leads to delayed diagnoses in young women.
3. Precision Medicine:
Knowing one’s BRCA status opens the door to PARP inhibitors and other targeted therapies that are more effective for mutation-related cancers. For Bank’s brother and Bank himself, this genetic "roadmap" dictated the course of treatment.
4. Normalizing the Conversation:
By speaking out, men like Doug Bank are reducing the stigma associated with "women’s cancers." Their participation in organizations like Sharsheret ensures that when cancer "enters the room," the whole family is equipped to face it.
Conclusion
Doug Bank’s journey from a confused 26-year-old patient to a 56-year-old advocate underscores a vital truth: in the realm of genetics, silence is a risk factor. As the medical community continues to refine its understanding of BRCA & Beyond, the inclusion of men in the conversation is no longer optional—it is a matter of life and death. For the Bank family, the "blessing" of Sharsheret and the power of genetic literacy turned a potential tragedy into a narrative of survival and empowerment.
About Sharsheret: Sharsheret is a national non-profit organization improving the lives of Jewish women and families living with or at increased genetic risk for breast or ovarian cancer through personalized support and educational outreach.
About the Author
